Akari Therapeutics plc has announced the filing of a new U.S. provisional patent application covering its second antibody drug conjugate $(ADC)$ program, AKTX-102, which targets CEACAM5-expressing solid tumors. The patent application includes new composition-of-matter claims around a novel antibody design and ADC constructs utilizing this antibody. AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and aims to address the challenging CEACAM5 oncology target, with potential to improve cytotoxic efficacy and activate both innate and adaptive immune responses, including activity against KRAS-mutated cancers. This filing expands Akari's intellectual property portfolio and builds on its earlier foundational patents related to PH1 payloads and ADC innovations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9642028-en) on January 26, 2026, and is solely responsible for the information contained therein.